Consensus Rating1
Buy
Highest Price Target1
$157.00
Lowest Price Target1
$90.00
Consensus Price Target1
$136.13

Ligand Pharmaceuticals (NASDAQ:LGND) Stock, Analyst Ratings, Price Targets, Forecasts

Ligand Pharmaceuticals Inc has a consensus price target of $136.13 based on the ratings of 8 analysts. The high is $157 issued by HC Wainwright & Co. on November 8, 2024. The low is $90 issued by Roth Capital on December 23, 2022. The 3 most-recent analyst ratings were released by RBC Capital, Benchmark, and Barclays on November 12, 2024, November 8, 2024, and November 8, 2024, respectively. With an average price target of $141.67 between RBC Capital, Benchmark, and Barclays, there's an implied 19.31% upside for Ligand Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Jun
3
Jul
4
Aug
4
Oct
5
Nov
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

RBC Capital
Benchmark
Barclays
Oppenheimer
HC Wainwright & Co.

1calculated from analyst ratings

Analyst Ratings for Ligand Pharmaceuticals

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Ligand Pharmaceuticals (LGND) stock?

A

The latest price target for Ligand Pharmaceuticals (NASDAQ:LGND) was reported by RBC Capital on November 12, 2024. The analyst firm set a price target for $140.00 expecting LGND to rise to within 12 months (a possible 17.90% upside). 22 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Ligand Pharmaceuticals (LGND)?

A

The latest analyst rating for Ligand Pharmaceuticals (NASDAQ:LGND) was provided by RBC Capital, and Ligand Pharmaceuticals maintained their outperform rating.

Q

When was the last upgrade for Ligand Pharmaceuticals (LGND)?

A

There is no last upgrade for Ligand Pharmaceuticals

Q

When was the last downgrade for Ligand Pharmaceuticals (LGND)?

A

There is no last downgrade for Ligand Pharmaceuticals.

Q

When is the next analyst rating going to be posted or updated for Ligand Pharmaceuticals (LGND)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ligand Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ligand Pharmaceuticals was filed on November 12, 2024 so you should expect the next rating to be made available sometime around November 12, 2025.

Q

Is the Analyst Rating Ligand Pharmaceuticals (LGND) correct?

A

While ratings are subjective and will change, the latest Ligand Pharmaceuticals (LGND) rating was a maintained with a price target of $130.00 to $140.00. The current price Ligand Pharmaceuticals (LGND) is trading at is $118.74, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch